Close Menu

GSK

NEW YORK (GenomeWeb) – Cepheid is collaborating with AstraZeneca, Cubist Pharmaceuticals, and GlaxoSmithKline to develop a rapid diagnostic test that can analyze multi-drug resistant pathogens and help doctors prescribe the most beneficial antibiotics for patients.

NEW YORK (GenomeWeb) – Quest Diagnostics announced today it will offer BioMérieux's BRAF mutation companion diagnostic for two of GlaxoSmithKline's molecularly targeted melanoma drugs, Tafinlar (dabrafenib) and Mekinist (trametinib).

Originally published June 3.
NEW YORK (GenomeWeb) – Data from two large studies that tested the efficacy of widely used targeted drugs in molecularly defined breast cancer and colorectal cancer populations failed to show superiority of one therapeutic strategy over another.

NEW YORK (GenomeWeb) – Genedata said this week that GlaxoSmithKline's biopharma research and development arm has selected its Genedata Biologics software to handle data management and workflow support needs.

NEW YORK (GenomeWeb) – Metabolon today announced a collaboration to provide metabolomic profiling services to GlaxoSmithKline.

Originally published April 29.
NEW YORK (GenomeWeb) — In garnering rights to GlaxoSmithKline's portfolio of oncology drugs, Novartis has access to several newly launched personalized cancer agents that the company hopes to drive to blockbuster status in coming years.

UK's CHMP Grants Positive Review of MEK Inhibitor Melanoma Drug Mekinist
The UK's Committee for Medicinal Products for Human Use (CHMP) recommended that the European Commission grant marketing authorization to GlaxoSmithKline's Mekinist (trametinib).

NEW YORK (GenomeWeb News) – In an effort to address the high failure rate of drug candidates in clinical studies, the Wellcome Trust Sanger Institute, the European Bioinformatics Institute, and GlaxoSmithKline have partnered to create a new center that will use genomics and big data technologies

A sequencing study of a bladder cancer patient from a Phase I clinical trial of Novartis' mTOR inhibitor Afinitor (everolimus) in combination with GlaxoSmithKline's VEGF inibitor Votrient (pazopanib) has found the most likely culprit for that patient's extraordinary response to

Pages

The Centers for Disease Control and Prevention estimates more people get sick and die from drug-resistant germs than previously thought, the Washington Post reports.

According to the Associated Press, three universities and a healthcare institution are sharing a gift of $1 billion.

New rules seek to limit the type of scientific and medical research that can be used to guide public health regulations, the New York Times reports.

In Nature this week: FreeHi-C approach simulates Hi-C data from interacting genome fragments, and more.